Zymeworks shares gain on promising data for cancer drug in development with Jazz PharmaceuticalsMarket Watch • 01/19/23
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaPRNewsWire • 01/19/23
2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go HigherThe Motley Fool • 01/11/23
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.The Motley Fool • 01/07/23
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/03/23
Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial dataGeekWire • 12/21/22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for ZanidatamabPRNewsWire • 12/21/22
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset EpilepsiesPRNewsWire • 12/05/22
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual MeetingPRNewsWire • 11/28/22
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)PRNewsWire • 11/18/22
STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENINGPRNewsWire • 11/14/22
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/10/22
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/09/22